TITLE

Candesartan reduced cardiovascular mortality and morbidity in chronic heart failure with low ejection fraction

PUB. DATE
May 2005
SOURCE
ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p60
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article cites a medical study which reports that candesartan reduced cardiovascular mortality and morbidity in chronic heart failure with low ejection fraction. Subanalysis of two randomized placebo-controlled trials, one adding candesartan in patients already taking angiotensin-converting enzyme (ACE) inhibitors and the other adding candesartan in patients who could not tolerate ACE inhibitors, was made. In patients with symptomatic chronic heart failure and reduced left-ventricular ejection fraction, candesartan reduced cardiovascular mortality, heart failure hospitalizations, and all-cause mortality, but increased adverse events.
ACCESSION #
17116516

 

Related Articles

  • Heart failure: ACE inhibitor cuts mortality, hospitalization rates.  // Geriatrics;Nov1991, Vol. 46 Issue 11, p88 

    The article reports that angiotensin converting enzyme (ACE) inhibitor cuts mortality, hospitalization rates. Treatment with an ACE inhibitor can significantly reduce mortality and hospitalization rates for patients with chronic congestive heart failure, according to a 5-year sponsored by the...

  • CORONA: Rosuvastatin reduced hospital stays, some adverse events in HF. Raible, Eric; Young, James B. // Cardiology Today;Jan2008, Vol. 11 Issue 1, p26 

    The article focuses on a study which examined the administration of rosuvastatin in patients with heart failure (HF). The study included 5,011 patients who were diagnosed with chronic, symptomatic systolic HF and were randomly selected to take rosuvastatin or placebo. It concluded that...

  • Good evidence supports use of ACE inhibitors in stable ischemic heart disease; little evidence exists for ARBs. Singh, Vibhuti // ACP Journal Club;5/18/2010, Vol. 152 Issue 5, p2 

    The article reports on a study that discusses advantages and disadvantages of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II-receptor blockers (ARBs) in ischemic heart disease (IHD). As stated, it compared ACE-Is or ARBs with placebo medicine in patients with stable IHD and...

  • The Role of Aldosterone Blockade in Patients with Hypertensive Heart and Cardiovascular Disease. Pitt, Bertram // Clinical Medicine Insights: Therapeutics;2010, Issue 2, p61 

    Aldosterone blockade has been shown to be effective in reducing total mortality in patients with severe heart failure due to systolic left ventricular dysfunction and in patients with heart failure post myocardial infarction. Increasing evidence suggests that aldosterone blockade alone and or in...

  • ACE INHIBITORS EFFECTIVE IN CORONARY ARTERY DISEASE.  // Pulse;11/2/2006, Vol. 66 Issue 41, p34 

    The article offers explanation on the effectiveness of Angiotensin-converting Enzyme (ACE) in decreasing mortality and morbidity in patients with coronary artery disease but without heart failure or systolic dysfunction. Overall mortality was lower in patients receiving an ACE inhibitors than in...

  • ACE inhibitors can prevent diabetes and heart failure.  // GP: General Practitioner;3/24/2003, p17 

    According to the results of a trial the angiotensin converting enzyme (ACE) inhibitors could prevent heart failure (HF) among patients at high risk of cardiovascular events. The ‘Heart Outcomes Prevention Evaluation’ (HOPE) study found ramipril cut the development rate of HF among...

  • Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Gheorghiade, Mihai; Albaghdadi, Mazen; Zannad, Faiez; Fonarow, Gregg C.; B�hm, Michael; Gimpelewicz, Claudio; Botha, Jaco; Moores, Shelley; Lewis, Eldrin F.; Rattunde, Henning; Maggioni, Aldo // European Journal of Heart Failure;Jan2011, Vol. 13 Issue 1, p100 

    Background Hospitalizations for acute heart failure syndromes (AHFS) are associated with high post-discharge mortality and readmission rates in spite of available therapies. Renin�angiotensin�aldosterone system (RAAS) antagonists improve outcomes in outpatients with heart failure (HF)...

  • Registrar: MRCGP Exam Update - Heart failure and beta-blockers. Newson, Louise // GP: General Practitioner;1/20/2006, p60 

    The article provides information on heart failure and beta-blockers. Despite strong evidence that beta-blockers increase the length and quality of life in people with heart failure, only 37 per cent of eligible patients are receiving a beta-blocker. Recent large, randomised, controlled trials...

  • Results From EMPHASIS-HF.  // MD Conference Express;Jan2011, p17 

    The article examines the effect of eplerenone, a selective aldosterone antagonist, on patients with NYHA Class II heart failure. It was found that the addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients. The primary outcome of cardiovascular (CV)...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics